- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06919640
Psilocybin med intrakraniel neural sensing (PINS)
This is an open-label, single-arm, pilot study exploring the neural, sensory, and cognitive effects of a single, medium dose of psilocybin in patients with chronic pain who already have implanted sensing-capable deep brain stimulation (DBS) devices. Outcomes include multi-site neural recording from previously placed ambulatory sensing-capable DBS devices, quantitative sensory and cognitive testing, and self-reports of pain. We hypothesize that psilocybin will change functional connectivity, decrease clinical and task-based pain reports, and improve cognitive functions.
Studieoversigt
Detaljeret beskrivelse
This is an open-label, single-arm, pilot study exploring the neural, sensory, and cognitive effects of a single, medium dose of psilocybin in patients with chronic pain who already have implanted sensing-capable deep brain stimulation (DBS) devices. Outcomes include multi-site neural recording from previously placed ambulatory sensing-capable DBS devices, quantitative sensory and cognitive testing, and self-reports of pain. We hypothesize that psilocybin will change functional connectivity, decrease clinical and task-based pain reports, and improve cognitive functions.
Undersøgelsestype
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
California
-
San Francisco, California, Forenede Stater, 94143
- University of California, San Francisco
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Currently implanted chronic brain sensing device (such as RC+S or Percept)
- Not currently enrolled in another trial
- Ability to speak and read English
- Able to attend all in-person and virtual visits
- No changes in medication or major surgical procedures anticipated for the trial
- Able to identify someone to accompany from the research unit at the end of drug administration day or agreement to have a study team member accompany them from the research unit
Exclusion Criteria:
- A health condition that makes this study unsafe or unfeasible, determined by study physicians
- Use of medication, vitamins, or supplements and unwilling or unable to discontinue medications that have problematic interactions with psilocybin
- Adulthood epilepsy or other seizure disorder
- Require supplemental oxygen
- Medical finding or diagnosis that would make participation in this trial unsafe
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Andet
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: 10 mg oral psilocybin
|
10mg oral psilocybin |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Changes in neural functional connectivity
Tidsramme: Drug administration to 90 days following
|
Measured by high-gamma coherence, cross-correlations, and Granger Causality |
Drug administration to 90 days following
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Subjective changes in pain
Tidsramme: Drug administration to 90 days following
|
Measured by subjective pain scales |
Drug administration to 90 days following
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Joshua Woolley, MD/PhD, University of California, San Francisco
- Ledende efterforsker: Prasad Shirvalkar, MD/PhD, University of California, San Francisco
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Neurologiske manifestationer
- Patologiske tilstande, tegn og symptomer
- Tegn og symptomer
- Smerte
- Kronisk smerte
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ring
- Alkaloider
- Indoler
- Indole alkaloider
- Indolizidiner
- Indolizines
- Tryptamines
- Psilocybin
Andre undersøgelses-id-numre
- 23-39870
- 175145 (Anden identifikator: FDA)
- PR#202507H (Anden identifikator: Research Panel of California)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .